SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors HOPE-3 cardiac results receiving the American Heart Associations Outstanding Research Award has renewed attention ahead of the FDAs deramiocel decision. Traders are largely optimistic about approval, but debate whether the cardiac recognition could affect the label, given the advisory committees negative vote on the heart indication and the applications focus on upper-limb function.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desks quarterly earnings beat and stronger-than-expected outlook, alongside an expanded share-repurchase authorization, sparked a sharp rally. Traders are divided on whether it signals a turnaround and could pressure short sellers or whether flat-to-declining sales, margin pressure and cautious management commentary justify the rallys fade.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zetas strong quarterly earnings beat and raised full-year guidance are driving attention, with traders praising accelerating growth and profitability while questioning why the shares saw sharp post-report swings. The debate centers on whether the pullback was a buyable reaction or a sell-the-news move.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

A rebound in gold is lifting gold-mining shares, with traders highlighting GDXs sharp bounce and renewed relative strength. The community is split between expecting the rally to continue and warning that volatile price action, elevated yields, and rate concerns could make the recovery fragile.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Labs quarterly results have sparked debate: strong revenue growth and a sharply expanded backlog were offset by a wider-than-expected loss and Neutrons first launch remaining no earlier than 2027, contributing to a post-report pullback after a sharp run-up. Bulls point to contracted demand and government support, while bears focus on execution delays, continued losses, and valuation.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Seas upcoming quarterly report is the main focus, with traders watching for clarity on a possible Monee listing and Sea Cloud spending after the stocks steep selloff. Some see the pullback as a value opportunity and anticipate a rebound, while others fear a weak outlook or further downside.

Dogecoin (DOGE) is a cryptocurrency . Users are able to generate DOGE through the process of mining. Dogecoin has a current supply of 156,683,462,860.16906072. The last known price of Dogecoin is 0.0697538 USD and is up 0.46 over the last 24 hours. It is currently trading on 1544 active market(s) with $547,539,013.79 traded over the last 24 hours. More information can be found at http://dogecoin.com/.

Dogecoin

Dogecoins prolonged drawdown and listless trading dominate the discussion: many traders expect further losses and question the meme coins value, while others are buying the dip and citing bullish technical signals or a possible reversal.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers quarterly results and reduced profit outlook are driving attention: an unexpected loss and sharply compressed margins overshadowed strong revenue growth, fueling the selloff. Traders are split between concerns about near-term profitability and the companys branded weight-loss drugs and expansion plans, with some bulls pointing to longer-term growth potential.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARAs quarterly results are driving attention, with traders weighing a revenue miss amid weaker Bitcoin prices against an EPS beat largely tied to unrealized digital-asset gains, debt reduction and a new buyback authorization. Optimism about its AI/HPC pivot and Exaion contract is tempered by frustration that larger site leases remain unsigned and doubts about execution.

Digital Turbine, Inc. engages in mobile growth platform solutions for advertisers, publishers, carriers, and device original equipment manufacturers. It operates through the following segments: On Device Solutions and App Growth Platform. The On Device Solutions segment consists of products and services that simplify the discovery and delivery of mobile apps and content media for device end users. The App Growth Platform segment provides Advertising Solutions and Ad Monetization Solutions. The company was founded on November 6, 1998 and is headquartered in Austin, TX.

Digital Turbine Inc

Digital Turbines quarterly results beat expectations and included higher revenue guidance, but traders are focused on compressed margins and whether revenue growth can translate into stronger profits. The sharp selloff despite the headline beat has divided the community, with some calling it an overreaction and others pointing to profitability, debt, and accounting concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of positive results from the companys Phase 2b clinical trial that evaluated the safety and efficacy of three doses of once-weekly, subcutaneous efinopegdutide (4 mg, 7 mg and 10 mg), an...

Can Moderna's First Cancer Therapy Win FDA Approval in 2027?

MRNA targets a year-end 2026 FDA filing for its personalized cancer therapy, intismeran, potentially paving the way for a regulatory decision in 2027.

INVA or MRK: Which Is the Better Value Stock Right Now?

INVA vs. MRK: Which Stock Is the Better Value Option?

Will Bristol Myers' Growth Brands Offset Eliquis Headwinds?

Bristol Myers' Growth Portfolio drives 57% of revenues, with key brands gaining traction to offset legacy drug declines and support growth.



MRK's 2027 Outlook Challenging, Long-Term Prospects Promising

Merck's 2027 growth faces generic pressures, vaccine weakness and Keytruda slowdown, but its expanding pipeline offers promising long-term potential.

Zacks Investment Ideas feature highlights: Moderna, AbbVie, Eli Lilly and Merck

MRNA hits a 52-week high after crushing Q3 earnings expectations and raising 2026 revenue guidance, but its nearly 800% rally raises valuation concerns.

Moderna (MRNA) Stock Hits 52-Week Highs After Q3 Earnings: Buy, Hold, or Sell?

Moderna stock has surged as much as 10% in Friday's trading session, reaching a fresh 52-week high after delivering much stronger-than-expected Q3 results.

Merck Stock Shows Sustained Strength: Time to Buy, Sell or Hold?

MRK's growth momentum faces patent and competitive risks as Keytruda demand and new launches support growth.

MRNA Q3 Earnings Beat on COVID Sales, Raises '26 Outlook, Stock Rises

Moderna's Q3 earnings beat estimates on strong COVID-19 vaccine sales, returning to profitability and boosting its 2026 revenue growth outlook.

IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D Costs

Iovance beat Q3 2026 earnings and revenue estimates as Amtagvi sales top $100 million, margins improve and R&D costs decline.

• Reported GAAP EPS of $2.49 down -3.49% YoY
• Reported revenue of $18.09B up 4.68% YoY
• Merck & Co. raised and narrowed full-year 2026 sales outlook to $66.8B to $67.3B and non-GAAP EPS outlook to $2.77 to $2.82, including one-time SciBrunch charge.

Merck & Co. reported lower GAAP gross margin and non-GAAP EPS year over year, alongside JANUVIA/JANUMET sales declines tied to generic competition following loss of U.S. market exclusivity.

Merck & Co. recorded growth in KEYTRUDA/KEYTRUDA QLEX and WINREVAIR sales, while Phase 3 INTerpath-001 results showed intismeran plus KEYTRUDA reduced recurrence-or-death risk by 42% versus KEYTRUDA alone.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets 

Equity

Extremely Bearish Sentiment

<ul class="summary-bullets"><li>Investors are watching for possible SLS009 updates as Sellas expects Q4 topline results from its Phase 2 study in newly diagnosed AML.</li><li>Sellas has a 600-square-foot booth at the Dec.12 to Dec.15 ASH meeting in New Orleans, in the same hall as several major drugmakers.</li><li>Q3 holdings disclosures showed stake increases by Pictet, Swiss Life, Arizona State Retirement System and Xponance.</li></ul>Shares of Sellas Life Sciences (SLS) snapped a four-day losing streak on Tuesday as retail investors looked ahead to abstracts from the American Society of Hematology (ASH), while fresh filings revealed increased holdings by Swiss asset managers and Arizona State Retirement System.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> jumped nearly 4% on Tuesday to $8.70.&nbsp;<h2 class="st-heading-2">SLS Bulls Count Down To ASH Abstracts</h2>ASH will release regular meeting abstracts on Wednesday, with late-breaking abstracts following on Dec.7.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.hematology.org/Meetings/Annual-Meeting/Abstracts?utm_source=chatgpt.com">&nbsp;</a>Sellas investors are watching for possible updates on SLS009, or Tambiciclib, its CDK9 inhibitor being studied in acute myeloid leukemia (AML). In August, Sellas said it expected fourth-quarter topline results from its Phase 2 study of SLS009 in newly diagnosed AML.&nbsp;The releases set the stage for the 68th ASH Annual Meeting and Exposition, running Dec.12 to Dec.15 in New Orleans. The event brings together blood-disease specialists, researchers and drugmakers, with more than 275 exhibitors expected.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.hematology.org/meetings/annual-meeting?utm_source=chatgpt.com">&nbsp;</a>Sellas has a 600-square-foot booth at the far end of Hall G, directly beside the poster area. Its 20-by-30-foot space, Booth 138, puts it in the same hall as large exhibits from Eli Lilly, Takeda, Genentech and AstraZeneca.&nbsp;Pfizer, Merck, Sanofi, AbbVie and Bristol Myers Squibb have booths across other halls, while Johnson &amp; Johnson is in Hall J, farther from Sellas. The broader exhibitor lineup includes GSK, Novartis, Amgen, Novo Nordisk, Daiichi Sankyo, Astellas, and Gilead and Kite Oncology.<h2 class="st-heading-2">Swiss Managers And Arizona Pension Raise Stakes</h2>Several institutional investors increased their stakes in Sellas during the third quarter, according to Sept.30 holdings disclosed in Tuesday filings tracked by Fiscal.ai.Pictet Asset Management Holding SA raised its stake by 15%, adding 3,704 shares to hold 27,688. Swiss Life Asset Management increased its stake by nearly 10%, adding 1,168 shares to bring its total to 13,292.Meanwhile, Arizona State Retirement System added 5,839 shares, lifting its holding by 12% to 55,391. Xponance increased its position by 3% to 19,025 shares.<h2 class="st-heading-2">Sellas’ Regal Enters Final Analysis Stage</h2>Sellas announced last week that its Phase 3 Regal trial had reached the prespecified 80th event, or death, clearing the way for database lock, unblinding and final statistical analysis.The randomized trial is testing Galinpepimut-S (GPS) as maintenance treatment for AML patients in second complete remission. Its primary endpoint is overall survival. “Reaching the 80th event represents a critical milestone in the REGAL trial,” CEO Angelos Stergiou said. Sellas expects preliminary topline results this quarter but has not set a release date.&nbsp;<h2 class="st-heading-2">How Do Retail Traders Feel About SLS?</h2>On Stocktwits, retail sentiment for SLS jumped to ‘extremely bullish’ from ‘bullish’ levels a day ago amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_732ac022d2.png" alt="sls ss.png" width="643" height="340"><figcaption>SLS sentiment and message volume as of November 3 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/Bio_buyout/message/668064034">anticipates</a> SLS009 data in the abstract release and said that the drug’s potential “should alone be 5X our current market Cap.” Another user&nbsp;<a href="https://stocktwits.com/Ewebb1018/message/668061540">said</a>, “it is not far fetched to think we may see data relating to GPS Expanded Access Program, and even more likely to see data regarding SLS-009.”<stembedurl>https://stocktwits.com/Ewebb1018/message/668061540</stembedurl>A separate trader also&nbsp;<a href="https://stocktwits.com/Cheffinance/message/668061442">distinguished</a> the ASH release from the pending Regal readout. “tomorrow they can say something about sls009, not about regal”<a href="https://stocktwits.com/Cheffinance/message/668061442">&nbsp;</a><stembedurl>https://stocktwits.com/Cheffinance/message/668061442</stembedurl>Institutional ownership also drew attention. “Institutions just keep loading up,” another user&nbsp;<a href="https://stocktwits.com/robcarroll/message/668067161">said</a>.<stembedurl>https://stocktwits.com/robcarroll/message/668067161</stembedurl>SLS stock has risen 135% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/super-micro-s-q1-revenue-nearly-quadruples-to-20-b-on-surging-ai-server-demand/cNGhsPWR9dk">Super Micro’s Q1 Revenue Nearly Quadruples To $20B On Surging AI Server Demand&nbsp;</a>

In this photo illustration, the SELLAS Life Sciences Group logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ASH will release regular meeting abstracts on Wednesday, followed by late-breaking abstracts on Dec.7.

SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets

Abbvie Inc

AMGEN Inc.

Bristol-Myers Squibb Co.

Glaxosmithkline plc - ADR

iShares Biotechnology ETF

Johnson & Johnson

Lilly(Eli) & Co

Novo Nordisk A/S

Novartis AG

Pfizer Inc

SELLAS Life Sciences Group Inc

Sanofi-Aventis

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Track MRK stock price, charts, news and real-time market activity on Stocktwits. Join the MRK message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around Merck & Co Inc stock.

MRK Stock Price Today - Merck & Co Inc News, Charts, Retail Sentiment

Buying the dip

Selling or trimming

Holding

Waiting for the investigation results to decide

Nvidia ($NVDA) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Stocktwits

) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Current Price	$148.76
Prev Close	$146.73
Open	$148.37
Dividend Yield	3.12%
50-Day Moving Average	$146.37
Beta	0.29
Avg. Volume	10.16M
PE Ratio	151.92

52-Week High	$156.92
52-Week Low	$87.26
Market Capitalization	$361.73B
EPS (Annual)	$7.28
Price to Book	8.17
Revenue Per Employee	$865,680.00

Feed

News

Sentiment

Earnings

Futures

Fundamentals

Info

MRK Fundamentals